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Homeostatic signaling systems are ubiquitous forms of biological regulation, having been
studied for hundreds of years in the context of diverse physiological processes including
body temperature and osmotic balance. However, only recently has this concept been
brought to the study of excitatory and inhibitory electrical activity that the nervous system
uses to establish and maintain stable communication. Synapses are a primary target of
neuronal regulation with a variety of studies over the past 15 years demonstrating that
these cellular junctions are under bidirectional homeostatic control. Recent work from
an array of diverse systems and approaches has revealed exciting new links between
homeostatic synaptic plasticity and a variety of seemingly disparate neurological and
psychiatric diseases. These include autism spectrum disorders, intellectual disabilities,
schizophrenia, and Fragile X Syndrome. Although the molecular mechanisms through
which defective homeostatic signaling may lead to disease pathogenesis remain unclear,
rapid progress is likely to be made in the coming years using a powerful combination
of genetic, imaging, electrophysiological, and next generation sequencing approaches.
Importantly, understanding homeostatic synaptic plasticity at a cellular and molecular
level may lead to developments in new therapeutic innovations to treat these diseases.
In this review we will examine recent studies that demonstrate homeostatic control of
postsynaptic protein translation, retrograde signaling, and presynaptic function that may
contribute to the etiology of complex neurological and psychiatric diseases.
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INTRODUCTION
Constraining nervous system activity within stable physiological
ranges is critical for robust and reliable brain function. However,
this stability must also permit the flexibility necessary for learn-
ing and memory to occur during the life experiences of an
organism. While various forms of Hebbian plasticity have been
shown to potentiate or weaken individual synaptic strengths,
these mechanisms are inherently destabilizing and would lead
to unconstrained activity if left unchecked. Homeostatic pro-
cesses have therefore been postulated to counteract the instability
generated through Hebbian forces, adjusting synaptic strengths
and intrinsic neuronal excitability to keep neural circuits func-
tioning within stable dynamic ranges throughout developmental,
experiential, and environmental challenges. While homeostatic
plasticity is fundamental and conserved in the nervous systems
of invertebrates, mammals, and humans, our understanding of
the underlyingmechanisms of these complex and robust signaling
systems has been quite limited.
In the late 1990s, Gina Turrigiano and colleagues reported
robust homeostatic synaptic plasticity in cultured rodent neu-
rons (Turrigiano et al., 1998). Around this same time, investi-
gations in Drosophila of postsynaptic receptor mutants at the
neuromuscular junction (NMJ) also revealed robust homeo-
static control of synaptic strength (Petersen et al., 1997; Davis
and Goodman, 1998b). Many groups have since described
homeostatic adaptations in diverse systems and organisms. Some
of these homeostatic processes are thought to require retrograde
signaling processes and presynaptic expression (Davis, 2006)
while others appear to be postsynaptically induced and expressed
(Turrigiano, 2008; Pozo and Goda, 2010).
Beyond conceptual ideas that disruptions in homeostatic
synaptic plasticity could lead, in principle, to neural excitabil-
ity disorders like epilepsy, compelling links with disease had
remained elusive. Although synaptic homeostasis has been
demonstrated to be a fundamental signaling system observed
in a variety of diverse organisms including crustaceans, C. ele-
gans, Drosophila melanogaster, rodents, and humans (Grunwald
et al., 2004; Turrigiano and Nelson, 2004; Marder and Goaillard,
2006; Pozo and Goda, 2010; Turrigiano, 2012; Vitureira et al.,
2012; Frank, 2013), direct associations with disease were unclear.
Of course, this was probably due in no small part to our poor
understanding, particularly on a molecular and cellular level, of
both homeostatic synaptic plasticity and neurological and psy-
chiatric diseases. However, work over the past 5 years has revealed
exciting new insights into both of these processes, which in turn
has led to the discovery of tantalizing links between diseases of
the nervous system and synaptic homeostasis. Although just a
beginning, a strong conceptual framework has now been estab-
lished as a foundation to investigate the extent to which defects
in homeostatic synaptic signaling could plausibly contribute to
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the disease pathogenesis of an array of neuropsychiatric and
neurological conditions.
These intriguing links include disease susceptibility genes on
both sides of the synapse that appear to help orchestrate the
homeostatic control of synaptic function (Table 1) (Pozo and
Goda, 2010; Wang et al., 2011a; Yizhar et al., 2011; Qiu et al.,
2012). Several theories have been proposed to explain the general
mechanisms of neural or synaptic dysfunction that might under-
lie these disorders (Kehrer et al., 2008; Sudhof, 2008; Yizhar et al.,
2011). Disruption or dysregulation of homeostatic synaptic plas-
ticity could be one cause of the excitation/inhibition imbalances
that have been recently implicated in cognitive and developmen-
tal deficits of the nervous system (Kehrer et al., 2008; Rubenstein,
2010). Indeed, it is tempting to speculate that the high rate of
seizures linked with many neurological and neuropsychiatric dis-
eases (Lhatoo and Sander, 2001; Leung and Ring, 2013) could be
explained, in part, by defects in homeostatic plasticity. Although
compelling studies suggest many of these processes target post-
synaptic receptor trafficking and synaptic scaling (Table 1), given
the topical focus of this FCN issue, this review will focus on the
disease-related pathways linked to the retrograde and presynaptic
control of homeostatic plasticity (Figure 1).
DISEASES ASSOCIATED WITH POSTSYNAPTIC
MODULATION OF PROTEIN SYNTHESIS AND HOMEOSTATIC
RETROGRADE SIGNALING
Several research groups have revealed a complex homeostatic
feedback system in the postsynaptic cell that serves to initiate
and convey retrograde signaling information back to the presy-
naptic neuron. These signaling molecules include retinoic acid
(RA) (Wang et al., 2011b), glial-derived TNF-alpha (Stellwagen
and Malenka, 2006), endocannabinoids (Zhang et al., 2009; Kim
and Alger, 2010), and brain-derived neurotrophic factor (BDNF)
(Jakawich et al., 2010; Henry et al., 2012). Both RA and BDNF
have been implicated in a variety of biological processes and dis-
eases, and multiple lines of evidence suggest that perturbations to
postsynaptic glutamate receptors lead to RA and BDNF synthesis
in the postsynaptic cell and subsequent alteration of synaptic pro-
tein synthesis and retrograde signaling that homeostatically mod-
ulate presynaptic function (Jakawich et al., 2010; Chen et al., 2012;
Henry et al., 2012; Kavalali andMonteggia, 2012). Interestingly, in
the case of several neuropsychiatric diseases including Tuberous
Sclerosis Complex and Fragile X Syndrome, imbalances in post-
synaptic protein synthesis have been implicated in their etiology.
These neuropsychiatric diseases are associated with intellectual
disability and autism spectrum disorders, and may arise due to
synaptic pathophysiology because of imbalances in the control
of postsynaptic protein synthesis (Auerbach et al., 2011; Martin
and Huntsman, 2012). Hence, a core postsynaptic step in homeo-
static signaling, control of local protein synthesis, may contribute
to retrograde signaling and the synaptic dysfunction contributing
to these diseases.
TUBEROUS SCLEROSIS COMPLEX (TSC)
Tuberous Sclerosis Complex is a genetic disease characterized
by formation of non-malignant tumors in the brain and other
organs (Osborne et al., 1991; Curatolo et al., 2008). This disease is
associated with seizures, intellectual disability, and autism, and is
the result of heterozygous mutations in the genes encoding TSC1
or TSC2, which encode proteins that together form a complex
that regulates activity of the mammalian Target of Rapamycin
(mTOR), a well-known regulator of mRNA translation (Zeng
et al., 2008; Curatolo andMoavero, 2012; Ryther andWong, 2012;
Talos et al., 2012). mTOR is a constituent of a complex that mod-
ulates protein translation by interacting with eIF4E and other
translation control factors, suggesting that aberrant regulation
of synaptic protein synthesis may contribute to the neurological
diseases associated with TSC.
Recent evidence from two established experimental models
for homeostatic synaptic plasticity has revealed that a postsy-
naptic signaling system, which regulates protein expression via
the mTOR pathway, is necessary for the retrograde control of
presynaptic release. Using rodent hippocampal neurons in cul-
ture, researchers have found that disruption of NMDA recep-
tor mediated miniature postsynaptic currents leads to a rapid
increase in postsynaptic protein synthesis and a compensatory
increase in postsynaptic glutamate receptor expression (Sutton
et al., 2006). Further, alterations in synaptic protein synthesis
via eIF4E and mTOR were found to be rapidly induced (within
1–2 h) following acute pharmacological blockade of AMPA recep-
tor function using CNQX (Jakawich et al., 2010; Henry et al.,
2012). Interestingly, one substrate of this postsynaptic signaling
system is BDNF, which is synthesized and released postsynapti-
cally where it activates presynaptic TrkA receptors and enhances
presynaptic function (Jakawich et al., 2010). Dysfunction in this
acute, retrograde modulation of presynaptic function via postsy-
naptic protein synthesis could plausibly contribute to the social,
cognitive, and excitability disorders observed in TSC and other
neurological diseases, including epilepsy.
This same pathway that modulates postsynaptic protein syn-
thesis and leads to the retrograde enhancement of presynaptic
transmission via the eIF4E and the TOR translational con-
trol factors has also been demonstrated in a separate model
system for presynaptic homeostatic plasticity, the Drosophila
NMJ (Penney et al., 2012). In this system, pharmacological or
genetic perturbations to postsynaptic glutamate receptor func-
tion, akin to the protocols used in rodent preparations dis-
cussed above, lead to a currently unknown retrograde sig-
nal the potentiates presynaptic release (Davis and Goodman,
1998b; Davis, 2006; Frank, 2013). Penney and colleagues found
that when levels of postsynaptic eIF4E or TOR proteins were
reduced, this led to a disruption in the compensatory home-
ostatic increase in presynaptic release normally observed fol-
lowing reduction of postsynaptic glutamate receptor function
(Penney et al., 2012). Although there is no obvious fly coun-
terpart of BDNF and the identity of the retromer is unknown,
it appears that fundamental, evolutionarily conserved parallels
between Drosophila and rodents in postsynaptic signaling via
eIF4E and TOR can modulate the retrograde, homeostatic con-
trol of presynaptic release. This fundamental property of synap-
tic homeostasis may be dysregulated during TSC. Interestingly,
expression of another protein, neurexin, is controlled by eIF4E
(Gkogkas et al., 2013), and has been linked with autism spec-
trum disorders (Sudhof, 2008), providing another putative link
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Table 1 | Genes and molecules required for homeostatic synaptic plasticity and linked with neurological diseases.
Molecule Disease Process References
Arc/Arg3.1 Angelman Syndrome Required for homeostatic control of postsynaptic AMPA
receptor trafficking in mammalian in vivo and in vitro
studies.
Gao et al., 2010; Beique et al.,
2011; Cao et al., 2013; Korb et al.,
2013
BDNF Autism, depression,
schizophrenia,
neurodegeneration, others.
Demonstrated to act as a retrograde messenger in
response to AMPA receptor blockade to induce
homeostatic presynaptic potentiation in hippocampal
neuronal cultures.
Jakawich et al., 2010
Ca2+ Channels Migraine, ataxia, epilepsy,
autism, ADHD, bipolar
disorder, depression, and
schizophrenia
Required for the expression of presynaptic homeostatic
plasticity at the Drosophila NMJ and cultured mammalian
neurons.
Terwindt et al., 1998; Cao and
Tsien, 2005; Frank et al., 2006;
Zhao et al., 2011; Smoller et al.,
2013
Dysbindin Schizophrenia Required presynaptically for the homeostatic increase in
synaptic vesicle release at the Drosophila NMJ.
Dickman and Davis, 2009; Zuo
et al., 2009
FMRP Fragile X Syndrome, autism,
intellectual disability
Necessary for the expression of RA-mediated homeostatic
increases in AMPA receptor expression and decreases in
GABA receptor expression in rodent hippocampal cultures.
Soden and Chen, 2010; Sarti et al.,
2013
MeCP2 Rett Syndrome (autism) Necessary for cell-autonomous homeostatic synaptic
scaling up and increases in cellular excitability in response
to reduced circuit activity in vitro, sensory deprivation
in vivo in mouse visual cortex, and for synaptic
down-scaling in mouse hippocampal culture.
Blackman et al., 2012; Qiu et al.,
2012; Zhong et al., 2012; Sala and
Pizzorusso, 2013
mTOR/eIF4E Tuberous Sclerosis Complex
(TCS)
Required postsynaptically for retrograde regulation of
presynaptic homeostatic potentiation at the Drosophila
NMJ and in mammalian neuronal cultures.
Penney et al., 2012; Talos et al.,
2012
Acetylcholine
receptors
(AChRs)
Myasthenia Gravis Loss of postsynaptic AChRs leads to presynaptic
homeostatic compensation in quantal content in human
muscle biopsies and mouse models.
Plomp et al., 1992, 1995
Narp Epilepsy Narp is necessary for homeostatic increases in interneuron
excitatory synapses in response to increased network
activity.
Chang et al., 2010
Neurexin
Neuroligin
Autism, schizophrenia,
Tourette’s Syndrome
Important for presynaptic homeostatic increases in quantal
content at the mouse NMJ.
Sons et al., 2006; Sudhof, 2008
NMDA
Receptors/eEF2
Depression Blocking NMDA receptors may prevent eEF2
phosphorylation, increasing translation, and possibly
leading to postsynaptic up-scaling of AMPA receptors.
Kavalali and Monteggia, 2012
Rab3GAP Warburg Micro and Martsolf
Syndrome
Required presynaptically for the induction and expression of
homeostatic increases in release probability at the fly NMJ.
Aligianis et al., 2006; Muller et al.,
2011
A summary genes and molecules associated with neurological diseases in a variety of systems that have been implicated in pre- and postsynaptic signaling
mechanisms driving the homeostatic control of synaptic strength.
between homeostatic regulation of the synapse and neuropsychi-
atric disorders.
FRAGILE X SYNDROME (FXS)
Fragile X Syndrome is a neuropsychiatric disorder character-
ized by intellectual disability, deficits in social interaction, and
associated neurological conditions such as seizures (Bagni and
Greenough, 2005; Bhakar et al., 2012). This genetic syndrome is
the most widespread single-gene cause of autism and inherited
form of mental retardation in boys (Hagerman and Hagerman,
2002; Hernandez et al., 2009). FXS is the result of mutations in
the fragile X mental retardation gene (fmr1), which encodes the
Fragile X Mental Retardation Protein (FMRP), and is necessary
for normal neural development (Lhatoo et al., 2001b). Research
over the past ten years has demonstrated that FMRP is a synaptic
RNA binding protein that represses translation of a subset of
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FIGURE 1 | Disease-related molecules and pathways required for
retrograde and presynaptic homeostatic signaling. Synaptic
components and processes involved in retrograde signaling and presynaptic
homeostatic plasticity that may also contribute to neurological and
neuropsychiatric diseases.
RNAs; hundreds of FMRP targets have recently been discovered
(Bassell andWarren, 2008; Costa-Mattioli et al., 2009; Zukin et al.,
2009; Darnell et al., 2011), leading to models in which both pre-
and post-synaptic RNAs are under modulatory translational con-
trol by FMRP (Feng et al., 1997; Stefani et al., 2004; Christie et al.,
2009; Akins et al., 2012).
The intercellular signaling molecule RA has been found to reg-
ulate homeostatic synaptic plasticity in rodent neuronal cultures
(Aoto et al., 2008; Maghsoodi et al., 2008; Soden and Chen, 2010;
Chen et al., 2012). Here, RA was demonstrated to be required
for the homeostatic increase in synaptic strength following post-
synaptic receptor perturbation (Aoto et al., 2008). Specifically,
blockade of excitatory activity was induced by TTX and APV
treatment, and RA was necessary for homeostatic postsynaptic
scaling through AMPA receptor insertion (Chen et al., 2012). A
novel cytosolic and synaptic function for RA was determined, as
synthesis of RAwas induced following this homeostatic challenge.
RA binds to its receptor RARalpha and in turn modulates post-
synaptic protein expression (Lane and Bailey, 2005; Chen et al.,
2012). Importantly, in addition to the function of RA in regulat-
ing postsynaptic homeostatic glutamate receptor scaling, RA was
also observed to have roles in modulating presynaptic function,
as reflected in increased mEPSC frequency (Wang et al., 2011b;
Chen et al., 2012). Intriguingly, FMRP is also necessary for RA-
mediated homeostatic plasticity at both excitatory and inhibitory
synapses (Soden and Chen, 2010; Sarti et al., 2013). In neurons
isolated from fmr1 mutant mice, bi-directional homeostatic scal-
ing was not observed, while other forms of plasticity remained
intact. These findings underscore the importance of tightly reg-
ulating synaptic protein synthesis in the context of homeostatic
plasticity and the possible neural diseases that may result from
dysfunction in this process.
The research described above provides an intriguing body of
evidence linking postsynaptic protein synthesis and retrograde
signals to both homeostatic synaptic plasticity and neurolog-
ical diseases. Several diseases show significant overlap in the
signaling pathways relevant to trans-synaptic homeostatic signal-
ing. Interestingly, mTOR activity has been implicated in TSC,
neurofibromatosis-1, FXS, and a variety of PTEN-associated con-
ditions (Gipson and Johnston, 2012). Regulation of postsynaptic
protein synthesis via mTOR and FMRP have both been shown to
disrupt mGluR dependent LTD (Auerbach et al., 2011). Indeed,
there are even links between FXS and BDNF signaling (Leung
and Ring, 2013). The question of how similar signaling systems
underlying homeostatic andHebbian (LTD/LTP)mechanisms are
integrated to ensure flexible yet stable synaptic function remains
an important area for future research.
Emerging evidence suggests that problems with retrograde sig-
naling may be involved in an array of autism spectrum disorders
beyond FXS and TSC. Another example of trans-synaptic sig-
naling being linked to cognitive disease is seen with neurexins
and neuroligins, cell-adhesion molecules that are known to regu-
late synaptic function (Sudhof, 2008). These molecules have been
linked with a variety of diseases including autism (Yan et al.,
2005; Szatmari et al., 2007; Kim et al., 2008), schizophrenia (Kirov
et al., 2008; Walsh et al., 2008), and other neuropsychiatric con-
ditions (Lawson-Yuen et al., 2008; Sudhof, 2008). Intriguingly,
neurexins have been found to be necessary for presynaptic home-
ostatic plasticity at the mammalian NMJ (Sons et al., 2006),
providing another possible link between homeostatic plasticity
and neuropsychiatric disease.
DISEASES ASSOCIATEDWITH PRESYNAPTIC MECHANISMS
OF HOMEOSTATIC PLASTICITY
CALCIUM CHANNEL AND HOMEOSTATIC SIGNALING IN MIGRAINE
AND EPILEPTIC DISEASES
Migraine is the most common neurological disease, thought to
affect 10–15% of the general population (Goadsby et al., 2002;
Wessman et al., 2007). Insight into the etiology of these often
debilitating headaches may be uncovered through the study of
familial hemiplegic migraine type 1 (FHM1), a rare, inherited
form of the disease (Ophoff et al., 1996). FHM1 is caused by mis-
sense mutations in P/Q type calcium channels, which are involved
in neurotransmitter release and presynaptic function (Zhang
et al., 1993; Lhatoo et al., 2001a). These mutations cause impair-
ments in the ability of these channels to conduct Ca2+ currents
triggered by action potentials (Kraus et al., 1998; Hans et al., 1999;
Cao et al., 2004). P/Q-type calcium channels have fundamental
roles in mediating fast synaptic transmission at nerve terminals.
Autosomal dominant mutations in the CACNA1A gene, which
encodes the voltage-gated P/Q-type calcium channel alpha1 sub-
unit, has also been associated with cerebellar ataxia, vertigo,
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epilepsy, and schizophrenia (see below) in addition to FHM
(Lhatoo et al., 2001a). CACNA1 and CACNB2 channelopathies
have also been implicated in several other diseases, including
autism, attention-deficit hyperactivity disorder, bipolar disorder,
and major depressive disorder, indicating that calcium channel
signaling may have crucial functions that, when perturbed, may
contribute to psychopathological susceptibility (Terwindt et al.,
1998; Lee et al., 2013; Smoller et al., 2013). These studies also
suggest a disruption in the balance of excitatory and inhibitory
activity that may ultimately lead to the pathogenic states of these
diseases.
Interestingly, mutations in the Drosophila P/Q calcium chan-
nel cacophony (cac) have been found to disrupt homeostatic
plasticity at the fly NMJ (Frank et al., 2006, 2009). Hypomorphic
mutations in cac lead to reduced presynaptic calcium influx
and prevent the retrograde, homeostatic increase in presynaptic
release. Recent studies using calcium imaging techniques demon-
strate that an acute increase in presynaptic calcium influx through
Cac is necessary for the expression of homeostatic plasticity
(Muller and Davis, 2012; Younger et al., 2013). In addition, reg-
ulation of presynaptic calcium influx is also required for homeo-
static synaptic plasticity in the mammalian hippocampus (Zhao
et al., 2011). Since calcium signaling is known to play a criti-
cal role in many aspects of neurotransmission, the function of
these channels in neurological disease is certainly not limited to
homeostatic plasticity. This topic is covered in more detail in a
forthcoming review (Frank, in review).
MYASTHENIA GRAVIS (MG)
Myasthenia gravis is an autoimmune disease that causes muscle
weakness and fatigue. In a majority of cases, a loss of post-
synaptic acetylcholine (ACh) receptors is observed at the NMJ
due to autoantibody production targeting these receptors. In
recordings from muscles obtained from MG patients and also
from toxin-induced animal models of the disease, miniature end-
plate potentials (mEPPs) show dramatically reduced amplitudes
(Plomp et al., 1992, 1995). However, evoked end-plate potentials
(EPPs) are not significantly reduced due to increased quantal con-
tent, indicating that homeostatic processes at the human NMJ,
like that of the fly NMJ, compensate for this perturbation of
postsynaptic receptor function (Cull-Candy et al., 1980; Plomp
et al., 1992, 1995; Davis and Goodman, 1998a). This homeostatic
increase in ACh release could compensate for the reduced post-
synaptic excitability of the muscle. However, if the compensation
is not sufficient to restore all EPPs to suprathreshold activation,
then defects in muscle activity would still be observed. Indeed, in
a subset of recordings mEPP amplitudes were below the detection
limit and showed smaller than normal EPPs, likely indicating lim-
itations in homeostatic compensation at these synapses (Plomp
et al., 1995). Furthermore, the increased release probability likely
contributes to increased short-term depression, leading to rapid
exhaustion of neurotransmitter vesicles and rapid-onset muscle
fatigue. Ultimately, disruption of postsynaptic receptor function
supersedes the homeostatic processes and major disease progres-
sion ensues.
A subclass of MG is caused by production of antibodies that
attack muscle specific kinase (MuSK) (Hoch et al., 2001; Viegas
et al., 2012), a postsynaptic receptor tyrosine kinase known to
be important in receptor clustering during NMJ synaptic devel-
opment and maintenance (DeChiara et al., 1996; Sanes and
Lichtman, 2001; Kong et al., 2004). In recordings from mus-
cles obtained from MuSK MG patients (Niks et al., 2010) and
frommice immunized against MuSK (Viegas et al., 2012), mEPPs
were found to be significantly reduced. However, in contrast to
the NMJ studies in mice and human discussed above, there was
no evidence of increased presynaptic release in MuSK-dependent
MG, indicating a lack of homeostatic expression (Niks et al.,
2010; Viegas et al., 2012). Compared to AChR-associated MG,
MuSK-related MG is more severe, is treatment-resistant, and
is observed more broadly in the musculature, affecting bulbar,
facial, and respiratory muscles as well (Evoli et al., 2003), which
is likely due, in part, to a lack of homeostatic compensation.
These experiments suggest that MuSK may be required as part
of the postsynaptic homeostatic signaling system that initiates a
retrograde, presynaptic change in release.
WARBURG MICRO AND MARTSOLF SYNDROME
Rab3 proteins are known to regulate vesicular membrane trans-
port and play a key role in modulating calcium-dependent neu-
rotransmitter release (Sakane et al., 2008). The activity of Rab3 is
regulated in part by Rab3 GTPase-activating protein (Rab3GAP),
which converts active Rab3-GTP to in the inactive GDP-bound
form. Rab3GAP is a heterodimeric protein composed of catalytic
and non-catalytic subunits, mutations of which cause Warburg
Micro syndrome and Martsolf syndrome (Aligianis et al., 2006).
Warburg Micro syndrome is an autosomal recessive disorder that
causes severe intellectual disability, ocular defects, and micro-
cephaly (Dursun et al., 2012). Martsolf syndrome shares many
clinical features with Warburg Micro syndrome, but is less severe
and is associated with milder cognitive dysfunction (Aligianis
et al., 2006). Recent evidence suggests that Rab3GAP is critically
involved in the induction and long-term maintenance of home-
ostatic synaptic plasticity. Drosophila Rab3GAP mutants do not
show homeostatic increases in neurotransmitter release at the
NMJ in response to pharmacological or genetic disruption of
postsynaptic glutamate receptors (Muller et al., 2011). Rab3GAP
appears to work through Rab3 GTPase to negatively regulate
the expression of presynaptic homeostatic plasticity. Thus, the
disruption of homeostatic synaptic plasticity may contribute to
the cognitive and developmental defects associated with these
Warburg Micro and Martsolf syndromes.
SCHIZOPHRENIA
Calcium signaling, through the implication of CACNA1, has been
implicated in several brain disorders including schizophrenia, and
a fly calcium channel, Cac, has been found to block homeo-
static synaptic plasticity (see above). In addition to these findings,
genetic screens in Drosophila have revealed unanticipated links
with schizophrenia. As alluded to above, the Drosophila NMJ has
been established as a model system to characterize homeostatic
synaptic plasticity. Pharmacological or geneticmanipulations that
reduce postsynaptic receptor function lead to a compensatory
increase in presynaptic release that precisely offsets the pertur-
bation and restores normal postsynaptic excitability (Davis and
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Goodman, 1998b; Davis, 2006; Frank, 2013). Given the rich
genetic resources available in flies, electrophysiology-based for-
ward genetic screens have recently been pioneered to identify
genes, that when mutated, lead to defective homeostatic synaptic
plasticity (Dickman and Davis, 2009; Muller et al., 2011).
One of the first genes identified from these screening efforts
was the Drosophila homolog of the vertebrate gene dysbindin
(Dickman and Davis, 2009). Interestingly, the human homolog
of this gene, DTNBP1, has been identified as a primary
schizophrenia susceptibility gene in a variety of Genome Wide
Association Studies (Ross et al., 2006; Zuo et al., 2009; Ghiani
and Dell’Angelica, 2011). In Drosophila, Dysbindin was found
to be required presynaptically for both the acute induction and
long term expression of synaptic homeostasis (Dickman and
Davis, 2009). Dysbindin localized to presynaptic vesicles and was
demonstrated to alter the calcium dependence of synaptic vesicle
release in a unique way, where mutants exhibited severely reduced
baseline release, but only at low external calcium concentrations,
whereas overexpression of dysbindin led to a potentiation of base-
line release, but only at higher external calcium levels (Dickman
and Davis, 2009). Subsequent work found that Snapin, a synap-
tic vesicle protein that binds to Dysbindin, was also required for
homeostatic synaptic plasticity and was necessary for the poten-
tiation of baseline synaptic transmission by Dysbindin (Dickman
et al., 2012). In rodent studies, dysbindin was found to be neces-
sary for proper synaptic glutamate release and neurotransmission
(Numakawa et al., 2004; Chen et al., 2008), while mouse mutants
even displayed behavioral deficits akin to schizophrenia-like con-
ditions (Chen et al., 2008). It is thus interesting to speculate
that Dysbindin may homeostatically tune synaptic strength, and
deficits in this process may give rise to cognitive and behavioral
conditions of relevance to the etiology of schizophrenia.
Dysbindin and Snapin are part of a larger protein complex
called the Biogenesis of Lysosome-related Organelles Complex-
1 (BLOC-1), composed of eight total subunits (Ghiani and
Dell’Angelica, 2011; Mullin et al., 2011). While the molecular
function of the BLOC-1 complex is unclear, it appears to be
involved in vesicle trafficking (Ghiani and Dell’Angelica, 2011;
Larimore et al., 2011). Consistent with such a role in the ner-
vous system, both Dysbindin and Snapin appear to function in
synaptic vesicle trafficking and may be involved in other synaptic
membrane trafficking pathways. Interestingly, another compo-
nent of the BLOC-1 complex, Muted, has recently been associated
with schizophrenia (Morris et al., 2008; Ryder and Faundez,
2009). These findings underscore the intriguing possibility that
defective synaptic membrane trafficking through components of
the BLOC-1 complex in the context of homeostatic synaptic plas-
ticity may contribute to the etiology of complex neuropsychiatric
diseases like schizophrenia.
CONCLUDING REMARKS
Tantalizing links have recently been uncovered that suggest synap-
tic processes necessary for the homeostatic control of synaptic
function, when defective, may contribute to the pathogene-
sis of a variety of neurological and neuropsychiatric diseases.
Importantly, several intriguing and novel genes and molecules
have been revealed to disrupt these complex and adaptive
homeostatic signaling systems (Figure 1). The challenge mov-
ing forward will be to understand how these individual genes
and molecules work together to integrate homeostatic informa-
tion and orchestrate stable cellular, synaptic, circuit, and systemic
functions in the brain. It is tempting to speculate that the eti-
ologies of many seemingly disparate neurological and neuropsy-
chiatric diseases share common dysfunctions in pathways related
to homeostatic synaptic plasticity. Indeed, a large genome-wide
study sponsored by the National Institute of Mental Health has
revealed a high degree of overlap in the genes responsible for five
of the most common neuropsychiatric diseases (Lee et al., 2013).
A combination of human genetic mapping and patient studies
coupled with innovative genetic, electrophysiological, and imag-
ing approaches in model systems are certain to reveal new insights
into the processes driving the homeostatic control of synaptic
function in health and disease.
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